DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for sickle cell disease — screening already-approved drugs against its 33-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSickle cell disease maps to a 33-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sickle cell disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Bruton tyrosine kinase (BTK) — BTK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 7h-pyrrolo[2,3-d]pyrimidin-4-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VXQ · 1.4 Å · ligand N-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl}benzamide (RQS). Experimental structure, not a prediction.
What the evidence adds up to
The three abstracts provided do not report any clinical trial results, survival data, response rates, or sample sizes. The 1999 abstract describes sickle cell disease as a vasculopathy leading to pulmonary complications such as acute chest syndrome and chronic sickle cell lung disease, and notes that new therapies based on molecular biology are being developed. The 1994 abstract discusses how the British health care system conceptualises and provides care for the condition, focusing on patient demographics and treatment attitudes. The 2016 abstract states that the disease is caused by a mutation in a haemoglobin gene, leading to red blood cell deformation, vessel occlusion, pain, and organ injury, and mentions correcting the mutation as a goal.
No drug, intervention, or experimental therapy is named or evaluated in any of these abstracts. There is no evidence of efficacy, no survival or response data, and no comparative outcomes. The abstracts are general reviews or commentaries, not primary research reports.
What is still missing: any clinical data on specific drugs or gene-editing approaches, patient stratification by genotype or complication history, funding for trials that test a defined intervention, and a trial design that measures concrete endpoints such as pain crisis frequency or hospitalisation rates.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Pulmonology · 1999 · 61 citations
The lung in sickle cell disease
AbstractSickle cell disease is the most common inherited disorder in African-Americans. Although the primary defect is hematological, the changes in the erythrocytes lead to a vasculopathy with multiorgan injury. The pulmonary complications, i.e., acute chest syndrome and chronic sickle cell lung disease, are significant causes of morbidity and mortality. The pulmonary manifestations result from a unique constellation of factors which come into play in sickle cell disease. Based on the growing understanding of the molecular and cellular biology of sickle cell disease, new therapies are being developed that are likely to ameliorate the natural history of this disease and its complications.
AbstractThis article considers sickle cell disease, focusing on the disease itself and exploring the way that the British health care system conceptualises the condition and provides care for sufferers. It examines the types of patient who are commonly affected by this condition and whether this influences the way the disease is viewed and treated.
AbstractSickle Cell Disease
Sickle cell disease is a genetic disorder caused by a mutation in one of the hemoglobin genes. This causes deformation of red blood cells and results in occlusion of blood vessels, severe pain, and progressive organ injury. To correct the mutation that causes this disease, De
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
